The deal-making and investment in New England’s enterprise IT sector continues.
Today, Stratoscale announced its acquisition of Cambridge, MA-based Tesora, a database-as-a-service provider.
Deal terms weren’t disclosed, but the purchase price probably wasn’t huge. Herzliya, Israel-based Stratoscale has raised about $70... Read more »
Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and... Read more »
Robots and artificial intelligence software could eventually render human workers obsolete in virtually every industry, but that shift will likely take at least 30 to 50 years to play out.
In the meantime, it’s important to focus on properly preparing people... Read more »
Amgen revealed on Thursday that its cholesterol lowering drug, evolocumab (Repatha)—part of a new class of heart treatments called PCSK9 inhibitors—has reduced the risk of heart attacks and strokes in a massive, 27,500 patient trial.
Thousand Oaks, CA-based Amgen (NASDAQ: AMGN... Read more »
Royalty Pharma, a New York-based company that buys up rights to royalty streams of potentially revenue-producing drugs, is paying $90 million for a for a chance to reap 4.5 percent royalty on possible sales of an experimental heart drug being... Read more »
Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though. A growing number of early-stage agtech startups are raising money and they’re pulling... Read more »
Despite the early and in some cases stunning results produced by gene therapy treatments in handfuls of hemophilia patients, significant questions remain about their durability, safety, and how broadly they’ll be used if they are ultimately shown to work. The first... Read more »
Four days after President Donald Trump issued an order to temporarily ban U.S. entry for people from seven Muslim-majority countries—and for all refugees—the drug industry’s two main lobbying groups have remained silent, even while individual executives in the industry have voiced... Read more »
When I last spoke to Sophie Vandebroek in December, it was for a kind of exit interview as she prepared to leave her longtime job as Xerox’s CTO and head of its worldwide research organization. We went over highlights of her... Read more »